Melanoma Researcher's Glioblastoma Trial Continues After His Death

Professor Richard Scolyer, the world's leading melanoma pathologist, died in June 2026 at 59, three years after his glioblastoma diagnosis. Before his death, he and colleague Georgina Long designed an experimental immunotherapy protocol—drawing from their melanoma breakthroughs—that made him the first brain cancer patient to receive personalized pre-surgery combination treatment. The clinical trial his protocol spawned continues in the United States, now testing whether the immunological principles that transformed melanoma outcomes can overcome glioblastoma's intractable biology.